Lv6
2250 积分 2021-07-23 加入
Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer
2天前
已完结
ATOMIC Energy — Biomarker-Bespoke Adjuvant Therapy for Colon Cancer
2天前
已完结
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
19天前
已完结
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
19天前
已完结
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
21天前
已完结
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
21天前
已完结
Risk-adaptive Therapy Guided by Dynamic ctDNA in Nasopharyngeal Carcinoma
21天前
已完结
Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer
23天前
已完结
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
23天前
已完结
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
28天前
已完结
皖公网安备34019202002308
